PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
Public ClinicalTrials.gov record NCT00548093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2, OPEN-LABEL, TWO ARM TRIAL TO EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS WITH ADVANCED NSCLC AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN AND FAILURE OF PRIOR TREATMENT WITH ERLOTINIB
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.
Study identification
- NCT ID
- NCT00548093
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2008
- Primary completion
- Mar 15, 2010
- Completion
- Jun 10, 2012
- Last update posted
- May 20, 2019
2008 – 2012
United States locations
- U.S. sites
- 19
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| City of Hope Medical Group | Pasadena | California | 91105 | — |
| City of Hope South Pasadena Cancer Center | South Pasadena | California | 91030 | — |
| Rocky Mountain Lions Eye Institute | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital, Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital, Anschutz Inpatient Pavilion | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Grady Health Systems | Atlanta | Georgia | 30303 | — |
| Emery University Hospital Midtown | Atlanta | Georgia | 30308 | — |
| Emory Clinic | Atlanta | Georgia | 30322 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| CCR, National Cancer Institute | Bethesda | Maryland | 20892 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute/Wayne State University | Detroit | Michigan | 48201 | — |
| Lawrence and Idell Weisberg Cancer Treatment Center | Farmington Hills | Michigan | 48334 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00548093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2019 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00548093 live on ClinicalTrials.gov.